Research review
What does DIM (diindolylmethane) do for women? What the research does and doesn't show
Human trials of DIM in women measure a shift in the ratio between estrogen metabolites, mostly in women with a personal or genetic history of hormone-sensitive cancer. The largest, most controlled trial (60 premenopausal women, 75 mg/day) found no significant change in that primary outcome; no trial has tested DIM against PCOS, fibroids, or menopause symptoms.
The evidence doesn't support DIM as a treatment for estrogen dominance, PCOS, fibroids, or menopause symptoms — no human trial has tested it for any of those specifically. What exists instead is a small set of trials measuring DIM's effect on estrogen-metabolite lab markers in women, mostly those with a personal or genetic history of hormone-sensitive cancer, and the largest, most controlled of those trials found no significant change on its main outcome.
What the evidence doesn't support
It doesn't support DIM as a treatment for PCOS, uterine fibroids, endometriosis, hot flashes or other menopause symptoms, or the popular marketing term "estrogen dominance," which isn't a formal diagnosis with its own trial data behind DIM. We didn't find a published human trial testing DIM against any of these conditions specifically. It also doesn't support the idea that DIM reliably "balances" or lowers estrogen in a general population of women — the trials that exist measured a shift in the ratio between different estrogen metabolites, not overall estrogen levels, and even that narrower marker was a null result in the largest trial.
What the trials found
A pilot study gave 19 postmenopausal women with a history of early-stage breast cancer either 108 mg/day of DIM or a placebo for 30 days. DIM significantly increased one urinary estrogen metabolite and cortisol compared with placebo, and the specific metabolite ratio researchers use as a proxy marker moved 47% in a favorable direction without reaching statistical significance in this small sample (PMID 15623462). A larger, more rigorous 2023 trial — double-blind, placebo-controlled, 60 premenopausal women with an unfavorable baseline ratio — tested a lower dose, 75 mg/day, for 30 days, and found no significant improvement on that same primary outcome. A secondary finding, a greater drop in body-fat percentage in the DIM group, was described by the study's own authors as needing further research, not a confirmed effect (PMID 36111381).
A one-year study gave 100 mg/day of DIM to 23 women carrying a high-risk BRCA gene mutation. Breast tissue density on MRI dropped slightly but statistically significantly, and estradiol and testosterone levels fell, compared with an untreated comparison group tracked over the same year. Side effects were mild. But the DIM group itself had no placebo arm, so the study can't rule out other explanations for the change (PMID 32458980).
A randomized trial gave 64 women with biopsy-confirmed moderate-to-severe cervical cell changes, already scheduled for a standard surgical procedure, either oral DIM (about 2 mg/kg a day) or placebo, for 12 weeks. DIM was well tolerated — mild nausea in 3% of the DIM group, no organ toxicity — but there was no statistically significant difference from placebo on any measured outcome, even though a high proportion of both groups improved (PMID 19939441). A broader review of cruciferous vegetables and cancer risk summarizes the field this way: DIM changes urinary estrogen-metabolite patterns in women, but that doesn't establish whether it lowers the risk of hormone-sensitive cancer in humans, and some experimental research has found the opposite, tumor-promoting effect with prolonged indole exposure (PMID 17317210).
| Population | Dose | Result |
|---|---|---|
| 19 postmenopausal women, breast cancer history | 108 mg/day, 30 days | Metabolite ratio moved favorably, not statistically significant |
| 60 premenopausal women, unfavorable ratio | 75 mg/day, 30 days | No significant change on primary outcome |
| 23 women, high-risk BRCA mutation | 100 mg/day, 1 year | Small breast-density drop vs. untreated comparison; no placebo arm |
| 64 women, cervical cell changes | ~2 mg/kg/day, 12 weeks | No significant difference from placebo on any outcome |
Questions people ask
What is DIM supplement for women?
It's a compound marketed around how the body metabolizes estrogen. Small human trials have measured it shifting the ratio between different estrogen metabolites in specific groups of women, mostly those with a history or genetic risk of hormone-sensitive cancer — with mixed results, and the largest, most controlled trial found no significant change in its primary outcome. See what is DIM (diindolylmethane)? for the underlying chemistry.
What does DIM do for women, and does it lower or increase estrogen?
No trial we reviewed found that DIM straightforwardly lowers or raises overall estrogen in women. What's been measured is a shift in the ratio between two estrogen metabolites — a narrower lab marker, not total estrogen — and results across the trials above were mixed, with the largest study null on that exact outcome.
Is DIM supplement good for women, and is it good for estrogen dominance?
"Estrogen dominance" is a popular marketing term, not a diagnosis with dedicated trial data behind DIM. The honest summary of the actual research: DIM has been studied mainly in women with a history or genetic risk of hormone-sensitive cancer, for lab and tissue markers, with mostly null or mixed results — not in a general population of women for a wellness goal.
Is DIM supplement good for PCOS, fibroids, or menopause?
We found no published human trial testing DIM against PCOS, uterine fibroids, endometriosis, or menopause symptoms such as hot flashes. That's an absence of evidence, not evidence it doesn't work — but no trial has tested it for any of these specifically.
When to talk to a doctor
PCOS, fibroids, endometriosis, and menopause symptoms that affect your quality of life are all worth discussing with a doctor, who can evaluate and treat the specific condition. DIM is not a treatment for any of them, and nothing in the research above supports using it as a substitute for a diagnosis or a treatment a doctor recommends. If you're pregnant, nursing, or have a personal or family history of a hormone-sensitive cancer, ask a doctor before adding any supplement proposed to affect hormone metabolism — see DIM and medications: what to check and who should not take DIM? for specifics.
Related reading: DIM benefits: what the research does and doesn't show, how much DIM should you take a day?, and what does DIM do for men?
Sources
- Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer A small pilot study found 108 mg/day of DIM for 30 days significantly increased one urinary estrogen metabolite and cortisol, compared with placebo, in 19 postmenopausal women with a history of early-stage breast cancer — but the specific metabolite ratio researchers use as a proxy marker moved in the same direction without reaching statistical significance.
- Effectiveness of 3,3'-Diindolylmethane Supplements on Favoring the Benign Estrogen Metabolism Pathway and Decreasing Body Fat in Premenopausal Women A 2023 double-blind, placebo-controlled trial of 60 premenopausal women found 75 mg/day of DIM for 30 days did not significantly change its primary estrogen-metabolite outcome; a secondary finding of a greater drop in body-fat percentage in the DIM group was flagged by the researchers themselves as needing further study, not a confirmed effect.
- 3,3-Diindolylmethane (DIM): a nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trial A one-year, single-arm study of 23 women with a high-risk BRCA gene mutation found daily 100 mg DIM was followed by a small but statistically significant decrease in breast tissue density on MRI and drops in estradiol and testosterone, compared with an untreated comparison group from the same clinic; side effects were mild, but with no placebo group in the DIM arm itself, the study can't rule out other explanations for the change.
- Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia A randomized trial of 64 women with moderate-to-severe cervical cell changes, comparing oral DIM (about 2 mg/kg/day) with placebo for 12 weeks, found DIM well tolerated (mild nausea in 3% of the DIM group, no organ toxicity) but no statistically significant difference from placebo on any outcome measured, despite a high rate of improvement in both groups.
- Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis A review of cruciferous vegetables and cancer risk found that while DIM and I3C change urinary estrogen-metabolite patterns in women, whether that translates into a lower risk of hormone-sensitive cancers in humans isn't known, and some experimental research has found the opposite (tumor-promoting) effect with prolonged exposure.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.